8-K
false0001690585 0001690585 2022-12-31 0001690585 2021-12-31 0001690585 2023-12-21 2023-12-21 0001690585 2022-01-01 2022-12-31 0001690585 2021-01-01 2021-12-31 0001690585 2023-09-11 0001690585 2023-09-11 2023-09-11 0001690585 2023-05-02 0001690585 2020-12-31 0001690585 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001690585 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001690585 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001690585 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001690585 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001690585 us-gaap:ComputerEquipmentMember 2022-12-31 0001690585 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001690585 us-gaap:ConstructionInProgressMember 2022-12-31 0001690585 us-gaap:CommonStockMember 2022-12-31 0001690585 dnth:ViridianLlcMember 2022-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember srt:MaximumMember dnth:FirstSelectedAntibodyMember dnth:DevelopmentMilestoneMember 2022-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember srt:MaximumMember dnth:FirstSelectedAntibodyMember dnth:CommercialMilestoneMember 2022-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember srt:MaximumMember dnth:DevelopmentMilestoneMember dnth:SecondSelectedAntibodyMember 2022-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember srt:MaximumMember dnth:SecondSelectedAntibodyMember dnth:CommercialMilestoneMember 2022-12-31 0001690585 dnth:DevelopmentMilestoneMember dnth:LigandPharmaceuticalsIncorporatedMember 2022-12-31 0001690585 dnth:DevelopmentMilestoneMember dnth:IontasLimitedMember dnth:FirstDevelopmentProgramMember 2022-12-31 0001690585 dnth:CommercialMilestoneMember dnth:IontasLimitedMember dnth:FirstDevelopmentProgramMember 2022-12-31 0001690585 dnth:DevelopmentMilestoneMember dnth:IontasLimitedMember dnth:SecondDevelopmentProgramMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember 2022-12-31 0001690585 dnth:TellusBioventuresLlcMember dnth:ZenasBiopharmaLimitedMember 2022-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember dnth:FairmountFundsMember 2022-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2022-12-31 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2022-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2022-12-31 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember 2022-12-31 0001690585 us-gaap:RestrictedStockMember 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember dnth:TrancheOneMember us-gaap:EmployeeStockOptionMember 2022-12-31 0001690585 us-gaap:DomesticCountryMember 2022-12-31 0001690585 us-gaap:StateAndLocalJurisdictionMember dnth:ExpirableMember 2022-12-31 0001690585 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001690585 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001690585 us-gaap:ComputerEquipmentMember 2021-12-31 0001690585 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001690585 us-gaap:ConstructionInProgressMember 2021-12-31 0001690585 us-gaap:CommonStockMember 2021-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001690585 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001690585 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001690585 dnth:ViridianLlcMember 2021-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember dnth:TellusBioventuresLlcMember 2021-12-31 0001690585 dnth:FairmountFundsMember dnth:ZenasBiopharmaLimitedMember 2021-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2021-12-31 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2021-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2021-12-31 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember 2021-12-31 0001690585 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001690585 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001690585 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001690585 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001690585 us-gaap:CommonStockMember 2023-09-11 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001690585 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001690585 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001690585 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001690585 dnth:WarrantsMember 2022-01-01 2022-12-31 0001690585 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001690585 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember 2022-01-01 2022-12-31 0001690585 dnth:IontasLimitedMember 2022-01-01 2022-12-31 0001690585 dnth:LigandPharmaceuticalsIncorporatedMember 2022-01-01 2022-12-31 0001690585 dnth:LicenseRevenueMember dnth:ZenasBiopharmaLimitedMember 2022-01-01 2022-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2022-01-01 2022-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001690585 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember 2022-01-01 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember dnth:TrancheTwoMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember us-gaap:EmployeeStockOptionMember dnth:CliffVestingMember 2022-01-01 2022-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001690585 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001690585 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001690585 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001690585 us-gaap:DomesticCountryMember dnth:IndefinitelyMember 2022-01-01 2022-12-31 0001690585 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001690585 us-gaap:RestrictedStockMember 2020-04-01 2020-04-30 0001690585 us-gaap:WarrantMember 2020-04-01 2020-04-30 0001690585 us-gaap:WarrantMember 2020-04-30 0001690585 us-gaap:RestrictedStockMember 2020-04-30 0001690585 dnth:ZenasBiopharmaLimitedMember dnth:UpfrontPaymentMember 2021-09-30 0001690585 dnth:ZenasBiopharmaLimitedMember 2022-01-01 2022-06-30 0001690585 dnth:ZenasBiopharmaLimitedMember dnth:UpfrontPaymentMember 2022-06-30 0001690585 dnth:ZenasBiopharmaLimitedMember dnth:MilestoneMember 2022-06-30 0001690585 dnth:ZenasBiopharmaLimitedMember 2020-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001690585 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001690585 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001690585 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001690585 dnth:WarrantsMember 2021-01-01 2021-12-31 0001690585 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001690585 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001690585 dnth:IontasLimitedMember 2021-01-01 2021-12-31 0001690585 dnth:AlloyTherapeuticsLlcMember 2021-01-01 2021-12-31 0001690585 dnth:LicenseRevenueMember dnth:ZenasBiopharmaLimitedMember 2021-01-01 2021-12-31 0001690585 dnth:ZenasBiopharmaLimitedMember 2021-01-01 2021-12-31 0001690585 us-gaap:PreferredStockMember dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001690585 us-gaap:PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001690585 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001690585 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001690585 dnth:TwoThousandAndNineteenStockPlanMember 2023-01-01 2023-05-15 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2019-07-19 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2019-07-19 2019-07-19 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2020-04-22 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2020-04-22 2020-04-22 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2020-12-01 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2020-12-01 2020-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2021-05-01 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember 2021-05-01 2021-05-31 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember 2022-04-01 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember 2022-04-01 2022-04-30 0001690585 us-gaap:CommonStockMember 2023-01-01 0001690585 dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001690585 dnth:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001690585 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001690585 us-gaap:RetainedEarningsMember 2022-12-31 0001690585 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001690585 us-gaap:PreferredStockMember dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2020-12-31 0001690585 us-gaap:PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2020-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001690585 us-gaap:RetainedEarningsMember 2020-12-31 0001690585 us-gaap:CommonStockMember 2020-12-31 0001690585 us-gaap:PreferredStockMember dnth:SeriesSeedOneRedeemableConvertiblePreferredStockMember 2021-12-31 0001690585 dnth:SeriesSeedTwoRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001690585 us-gaap:PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2021-12-31 0001690585 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001690585 us-gaap:RetainedEarningsMember 2021-12-31 iso4217:USD xbrli:shares xbrli:pure iso4217:GBP utr:Year utr:Month iso4217:USD xbrli:shares dnth:OperatingSegments dnth:ReportingSegments utr:Y
SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2023
DIANTHUS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
|
|
|
(State or Other Jurisdiction |
|
|
|
|
|
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
|
|
|
Registrant’s Telephone Number, Including Area Code:
929 999-4055
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
| Common Stock, $0.001 Par Value |
|
DNTH |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As previously reported, on September 11, 2023, Dianthus Therapeutics, Inc. (the “
”) effected a
reverse stock split of its common stock (the “
”) immediately prior to the consummation of the reverse merger with Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.) (“
”). At the effective time of the reverse merger, the Company issued common stock to Former Dianthus stockholders based on an exchange ratio of approximately 0.2181 shares of common stock for each share of Former Dianthus capital stock (which exchange ratio reflects the Reverse Stock Split) (the “
”). To reflect the Reverse Stock Split and the Exchange Ratio, the audited financial statements of Former Dianthus for the years ended December 31, 2022 and 2021 and the related notes thereto have been recast and are filed herewith as Exhibit 99.1. There have been no other changes to such financial statements.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
DIANTHUS THERAPEUTICS, INC. |
|
|
|
| Date: December 21, 2023 |
|
By: |
|
|
|
|
|
|
|
|
Adam M. Veness, Esq.
SVP, General Counsel and Secretary |
